How do you manage venous thromboembolic events or bleeding events in RCC or HCC patients on anti-angiogenic TKIs?
Arterial events have clear instructions to permanently discontinue on the FDA label. Especially in HCC without many other treatment options, given that VTE and bleeding events are quite common with these drugs, what is your approach?
Answer from: Medical Oncologist at Academic Institution
I generally would not discontinue for a bleeding event for an RCC pts on anti-VEGF therapy. I may hold drug while managing the event if I can control the source of bleeding, but given most options include such an approach would restart cautiously. Similarly for venous thrombotic events I would manag...
Sign in or Register to read more